00:56 , Oct 25, 2014 |  BC Extra  |  Company News

Venture Tracks

PureTech Ventures (Boston, Mass.) named Robert Horvitz, Joi Ito and Raju Kucherlapati as senior partners. Horvitz, a Nobel Laureate, is a professor at Massachusetts Institute of Technology and a co-founder of Epizyme Inc. (NASDAQ:EPZM) and...
07:00 , May 12, 2014 |  BC Week In Review  |  Company News

Amgen, ImmunoGen, Oxford BioTherapeutics deal

Oxford received exclusive, worldwide rights to Xenomouse antibodies generated by Amgen and to ImmunoGen's TAP antibody-conjugate technology for an undisclosed target. Oxford will use the antibodies and TAP technology to develop an antibody-drug conjugate (ADC)...
07:00 , Oct 14, 2013 |  BioCentury  |  Strategy

Reviving Merck

As Merck & Co. Inc. 's new head of R&D, Roger Perlmutter plans to refocus and prune the pharma's pipeline of 31 Phase II and Phase III programs. But with half of its Phase III...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Company News

Amgen, ImmunoGen deal

Amgen exercised a third option for an exclusive, worldwide license to use ImmunoGen's Targeted Antibody Payload (TAP) technology to develop cancer therapeutics to an undisclosed target. TAP technology uses antibodies to deliver antitumor agents to...
08:00 , Feb 27, 2012 |  BioCentury  |  Emerging Company Profile

Kymab: More mAb diversity

Kymab Ltd. is developing its Kymouse transgenic mouse platform to generate a greater repertoire of human mAbs than it says can be done with competing technologies. With the Wellcome Trust backing the newco, management plans...
08:00 , Nov 21, 2011 |  BC Week In Review  |  Company News

Amgen, ImmunoGen deal

ImmunoGen received a $1 million milestone payment from Amgen under a 2000 deal granting Abgenix Inc. rights to ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology. Amgen acquired Abgenix in 2006. The payment was triggered by...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Amgen, ImmunoGen deal

ImmunoGen received a $1 million milestone payment from Amgen under a 2000 deal granting Abgenix Inc. rights to ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology. Amgen acquired Abgenix in 2006. The payment was triggered by...
08:00 , Feb 17, 2011 |  BC Innovations  |  Targets & Mechanisms

EMMPRIN's new clothes

EMMPRIN dropped off the drug discovery map in 2003 when Abgenix Inc. 's antibody against the target failed in a Phase II/III trial to treat graft-versus-host disease. Now, findings from Canadian researchers suggest it might...
08:00 , Jan 31, 2011 |  BioCentury  |  Strategy

Selling mouse futures

The two most popular mouse platforms to discover human antibodies, Abgenix Inc. 's XenoMouse and Medarex Inc. 's HuMAb Mouse, have been licensed only once since Abgenix was acquired by Amgen Inc. in 2005 and...
08:00 , Jan 24, 2011 |  BC Week In Review  |  Company News

Amgen, Boehringer Ingelheim deal

Boehringer will acquire Amgen's development and manufacturing facility in Fremont, Calif., for an undisclosed sum. Boehringer said the acquisition will strengthen its global Contract Manufacturing Business. The deal has been approved by the boards of...